- The biology of the biomarkers used in the aGVHD Algorithm assays
- How MAGIC Algorithm Probability (MAP) testing classifies patients for long term risk of severe GVHD and non-relapse mortality identify in pre-symptomatic, symptom onset, and post-treatment HCT patients
- How to interpret MAPs as response biomarkers
- Case studies recommending treatment approaches guided by MAPs
Length of Presentation: 56 minutes (part 2 of 4)
Presented by:
- Dr. James Ferrara, MD
Ward-Coleman Chair in Cancer Medicine
Professor of Pediatrics & Medicine
Icahn School of Medicine at Mount Sinai - Dr. Ryotaro Nakamura, MD
Hematologist - Oncologist
Associate Professor of Department of Hematology & Hematopoietic Cell Transplantation; Co-director, Center for Stem Cell Transplantation
